These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 28202530)

  • 1. Therapeutic Potential of Bacteria against Solid Tumors.
    Hatzikirou H; López Alfonso JC; Leschner S; Weiss S; Meyer-Hermann M
    Cancer Res; 2017 Apr; 77(7):1553-1563. PubMed ID: 28202530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity.
    Kianmanesh A; Hackett NR; Lee JM; Kikuchi T; Korst RJ; Crystal RG
    Hum Gene Ther; 2001 Nov; 12(17):2035-49. PubMed ID: 11747595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo.
    Li Q; Li L; Shi W; Jiang X; Xu Y; Gong F; Zhou M; Edwards CK; Li Z
    Cancer Immunol Immunother; 2006 Dec; 55(12):1470-9. PubMed ID: 16555058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular-targeted TNFα improves tumor blood vessel function and enhances antitumor immunity and chemotherapy in colorectal cancer.
    Lu L; Li ZJ; Li LF; Wu WK; Shen J; Zhang L; Chan RL; Yu L; Liu YW; Ren SX; Chan KM; Cho CH
    J Control Release; 2015 Jul; 210():134-46. PubMed ID: 26003042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
    Menssen HD; Harnack U; Erben U; Neri D; Hirsch B; Dürkop H
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):499-507. PubMed ID: 29327244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cells are required for tumor-targeting Salmonella in host.
    Lee CH; Hsieh JL; Wu CL; Hsu HC; Shiau AL
    Appl Microbiol Biotechnol; 2011 Dec; 92(6):1251-60. PubMed ID: 21667275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.
    Balza E; Mortara L; Sassi F; Monteghirfo S; Carnemolla B; Castellani P; Neri D; Accolla RS; Zardi L; Borsi L
    Clin Cancer Res; 2006 Apr; 12(8):2575-82. PubMed ID: 16638868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salmonella typhimurium Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β.
    Kim JE; Phan TX; Nguyen VH; Dinh-Vu HV; Zheng JH; Yun M; Park SG; Hong Y; Choy HE; Szardenings M; Hwang W; Park JA; Park S; Im SH; Min JJ
    Theranostics; 2015; 5(12):1328-42. PubMed ID: 26516371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
    Robert B; Mach JP; Mani JC; Ychou M; Folli S; Artus JC; Pèlegrin A
    Cancer Res; 1996 Oct; 56(20):4758-65. PubMed ID: 8840995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models.
    Lanuti M; Rudginsky S; Force SD; Lambright ES; Siders WM; Chang MY; Amin KM; Kaiser LR; Scheule RK; Albelda SM
    Cancer Res; 2000 Jun; 60(11):2955-63. PubMed ID: 10850443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy.
    Lee CH; Wu CL; Tai YS; Shiau AL
    Mol Ther; 2005 May; 11(5):707-16. PubMed ID: 15851009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of antiinfectious potential of recombinant tumor necrosis factor-alpha].
    Kalinin IuT; Pustoshilova NM; Denisov LA; Afanas'ev SS; Marchenko VI; Vorob'ev AA; Rubal'skiĭ OV; Shcherbakov GIa
    Vestn Ross Akad Med Nauk; 1998; (10):29-32. PubMed ID: 9846109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer therapeutic potential of combinatorial immuno- and vasomodulatory interventions.
    Hatzikirou H; Alfonso JC; Mühle S; Stern C; Weiss S; Meyer-Hermann M
    J R Soc Interface; 2015 Nov; 12(112):. PubMed ID: 26510827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
    Tsujie M; Uneda S; Tsai H; Seon BK
    Int J Oncol; 2006 Nov; 29(5):1087-94. PubMed ID: 17016638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Brucella melitensis M16 infection model in mice treated with tumor necrosis factor-alpha inhibitors.
    Kutlu M; Ergin Ç; Şen-Türk N; Sayin-Kutlu S; Zorbozan O; Akalın Ş; Şahin B; Çobankara V; Demirkan N
    J Infect Dev Ctries; 2015 Feb; 9(2):141-8. PubMed ID: 25699488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying the therapeutic requirements and potential for combination therapy to prevent bacterial coinfection during influenza.
    Smith AM
    J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):81-93. PubMed ID: 27679506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell augments the antitumor activity of tumor-targeting Salmonella.
    Lee CH; Hsieh JL; Wu CL; Hsu PY; Shiau AL
    Appl Microbiol Biotechnol; 2011 May; 90(4):1381-8. PubMed ID: 21360146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular-targeted TNFα and IFNγ inhibits orthotopic colorectal tumor growth.
    Shen J; Li ZJ; Li LF; Lu L; Xiao ZG; Wu WK; Zhang L; Li MX; Hu W; Chan KM; Cho CH
    J Transl Med; 2016 Jun; 14(1):187. PubMed ID: 27342639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth.
    Mobergslien A; Peng Q; Vasovic V; Sioud M
    Oncotarget; 2016 Nov; 7(46):75940-75953. PubMed ID: 27713158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.